Gerald Lam

Since joining Kirkland, Gerald’s representative matters have included:

• Advised GLP Pte. Ltd. and the consortium offeror (comprising the Fung family and GLP) in the proposed privatization of Li & Fung, a multinational supply-chain management company listed on the Hong Kong Stock Exchange (HKSE: 494)
• Conducted an internal investigation on behalf of a Hong Kong-listed logistics, financial services and engineering company in response to suspected financial misconduct, fraud, and breach of fiduciary duties by directors in Singapore
• Acted as counsel to a multinational software company in an antitrust investigation before the Hong Kong Competition Commission
• Defended a Hong Kong-listed information and communications technology client in criminal prosecution by Hong Kong Customs and Excise for offences under the Import and Export Ordinance relating to technology imports
• Advised Cushman & Wakefield (NYSE: CWK), a leading global real estate services firm, on international risk compliance in the formation of a new asset services company with Vanke Service
• Conducted an anti-corruption and sanctions compliance review and risk assessment of a leading global private equity firm’s investment portfolios in India
• Providing international risk advice to a NYSE-listed investment management company on a substantial minority investment in a leading digital technology company in the Philippines, which focused on the development of digital payments, digital finance and marketing technology platforms
• Advised a leading global investment firm on anti-corruption and sanctions due diligence in relation to a proposed substantial leveraged buyout of a listed video game publisher specializing in online PC and mobile games in Japan, the PRC, Korea and Southeast Asia
• Advised a prominent asset investment firm on international anti-corruption and sanctions risks in relation to a controlling investment in an investment trust in India
• Conducted an anti-bribery and internal controls investigation for a prominent global alternative asset investment firm in relation to potential allegations of fraud and misconduct relating to its portfolio investment in Saudi Arabia

Prior to joining Kirkland, Gerald’s representative matters included:

Compliance and Regulatory Counseling

• Acted as legal and compliance counsel (on secondment) for a multinational pharmaceutical company and supported its operations in China, Hong Kong, Macau, Malaysia and Singapore. Provided advice on areas such as local pharmaceutical law and regulations (in various jurisdictions such as Malaysia and China), FCPA and local anti-bribery laws as they relate to market operations, clinical studies, and formulary and market access.

• Conducted anti-bribery and corruption / FCPA due diligence on various corporate transactions.

• Advised multinational companies on the regulatory requirements governing the sale and marketing of pharmaceutical products and medical devices in various jurisdictions, including off-label and unapproved marketing issues.

• Assisted a U.S.-listed Fortune 500 pharmaceutical and manufacturing company in carrying out a proactive compliance assessment of its Japan business. 

• Advised a multinational surgical products company on its distribution, co-marketing and promotion agreements in Hong Kong and China.

• Advised various multinational fintech and technology companies on cross-border transfers of data, potential breaches of direct marketing consent and notification requirements, and on the data anonymization and data protection requirements in China, Hong Kong and Singapore.

• Advised banks, payment service providers, and other financial technology companies on payment card regulations and related money lending, data protection and licensing issues.

Corporate Internal Investigations

• Conducted multiple anti-bribery and books and records/internal controls investigations for a major U.S.-listed pharmaceutical, medical devices, and consumer goods manufacturer in Indonesia and Japan into allegations involving fabricated documentation, inappropriate interactions with HCPs and government officials, third party distribution risks and inappropriate involvement in the preparation of an investigator-initiated clinical research scientific protocol.

• Conducting an anti-bribery and books and records investigation in Myanmar for a major U.S.-listed manufacturer in relation to a series of compliance issues involving the company’s subsidiary and distributor.

• Conducted an internal investigation on behalf of a major multinational company’s Chinese operating entity in relation to allegations of collusion with distributors and customers to inflate its sales figures.

Sidley Austin LLP, 2015–2018

Minter Ellison, 2011–2015